Neutral/Negative Catalysts
- Near-term technical digestion: MACD weakening + price sitting near pivot implies the stock may chop before clearing 190–193 resistance.
- “Catalyst-light” gap risk (Street view): one major firm highlighted fewer major catalysts after the post-FDA-acceptance run-up until the key decision date window.
- Profitability not yet there: losses widened YoY despite revenue growth, which can cap multiple expansion if spending accelerates faster than sales.
